All news articles for September 2022


Building up Australia’s vaccine manufacturing capacity

By Rachel Arthur

Almost all of Australia’s vaccines are imported: creating a potential crisis in a pandemic. As a result, the country is setting out its strategy for developing vaccine manufacturing capabilities.


Rocket Pharmaceuticals to acquire Renovacor

By Rachel Arthur

Rocket Pharmaceuticals, a late-stage, clinical biotech advancing a pipeline of genetic therapies for rare childhood disorders, will acquire Renovacor: helping it strengthen its position in AAV-based cardiac gene therapy.


bluebird bio gets green light for Skysona gene therapy in the US

By Rachel Arthur

The US Food and Drug Administration (FDA) has granted Accelerated Approval for bluebird bio’s Skysona (elivaldogene autotemcel), also known as eli-cel, to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral...

Join us for our free-to-attend Bioprocessing 4.0 webinar!

Join us for our free-to-attend Bioprocessing 4.0 webinar!

By Rachel Arthur

What role does Bioprocessing 4.0 have to play in the ongoing energy crisis? How can we train and develop the right skills for the industry? These are just some of the questions we’ll ask in our free-to-attend webinar tomorrow!

© GettyImages/Richard Drury

Asia-Pacific attracts 50% of global clinical trials

By Jane Byrne

The Asia-Pacific (APAC) region was the largest contributor to the global clinical trial landscape from 2017 to 2021, accounting for more than 50% of conducted trials during the analysis period, found research by GlobalData.